SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	Bradykinin B2 receptor (BDKRB2; B2R)	Patient samples and rat brain slice experiments suggest that B2R antagonists could help treat brain cancers. In patient samples, glioma malignancy correlated with high BR2 expression. In rat brain slices seeded with human malignant glioma cells, bradykinin increased both glioma cell migration and the number of glioma cells attached to blood vessels compared with no treatment. In the glioma-seeded and bradykinin-treated rat brain slices, B2R antagonists inhibited glioma cell attachment to blood vessels compared with no treatment. Ongoing studies include testing B2R antagonists in rodent models of brain cancer. sanofi-aventis Group and Shire plc market the peptidomimetic B2R antagonist icatibant (JE049) to treat angioedema. Abbott Laboratories' nonpeptide B2R antagonist anatibant (LF16-0687) is in Phase II testing to treat shock/trauma.	Unpatented; licensing status not applicable	Montana, V. & Sontheimer, H. *J. Neurosci.*; published online March 30, 2011; doi:10.1523/JNEUROSCI.3825-10.2011 **Contact:** Harald Sontheimer, The University of Alabama at Birmingham, Birmingham, Ala. e-mail: sontheimer@uab.edu

SciBX 4(14); doi:10.1038/scibx.2011.393
Published online April 7, 2011